Lonza Group AG
🇨🇭XSWX.LONNSwitzerlandNot reported
PriceCHF 569.20-0.60 (-0.11%)
Latest anomalies
Neutral 2 detected in the last 120 days
- High: 4
- Medium: 2
- Low: 0
12-1M momentum: flipped sign, from negative to positive
Volume: a spike above the 20-day average
Debt to assets: a sudden spike above its trailing quarter average
Debt to equity: a sudden spike above its trailing quarter average
Long-term debt to equity: a sudden spike above its trailing quarter average
Free with a Finzer account.
Profile
- Switzerland
Identity
- Exchange
- SIX Swiss Exchange . XSWX
- Type
- Stock
- ISIN
- CH0013841017
- CUSIP
- Not reported
Company
- Employees
- 19,299
- Headquarters
- Basel, United Kingdom
- Website
- https://www.lonza.com
Market
- Shares outstanding
- 69.8M
- Market cap
- CHF 39.93B
Key dates
- Next earnings
- Jan 28, 2027
Highlights
- Market cap
- CHF 39.93B
- EPS LTM
- CHF 25.16
- P/E LTM
- 22.62calculatedCalculated by Finzer, not reported by the data provider.
- Div yield
- 1.28%calculatedCalculated by Finzer, not reported by the data provider.
Fundamentals (LTM)
- Revenue
- CHF 7.67B+6.53%up year on year
- Net income
- CHF 1.87B-43.13%down year on year
- Gross margin
- 37.51%-3.2%down year on year
- Free cash flow
- -CHF 714M-15.53%down year on year
Latest news
News is not sourced for this exchange.
Business summary
Lonza Group AG is listed on SIX Swiss Exchange (Switzerland) under the ticker LONN. Its market capitalisation is CHF 39.93B, from 69.8M shares outstanding, as of . Across the 249 trading sessions to the shares traded between CHF 454.60 and CHF 597.80, and the last close of CHF 569.20 sits 80% of the way up that range. The company is headquartered in Basel, United Kingdom, and employs about 19,299 people. The same company also trades as 0QNO on London Stock Exchange.
Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Biologics; Small Molecules; Cell & Gene; and Capsules & Health Ingredients segments. The Biologics segment engages in the contract development and manufacturing of biopharmaceuticals for clinical and commercial manufacturing needs throughout the product lifecycle, including drug substance and drug product manufacturing. Its Small Molecules segment provides integrated development and manufacturing services for small molecule drug substances and their intermediates. This segment also supports customers across aspects of design, development, and manufacturing, such as particle engineering and drug product packaging. The Cell & Gene segment develops technologies and platforms that industrialize the manufacturing processes and production of cell and gene therapies; offers contract development and manufacturing services, and regulatory support for a range of allogeneic and autologous cell therapies, and exosome-based therapies, as well as viral vector gene therapies. This segment also provides Cocoon platform, a closed automated system for patient-scale cell therapy manufacturing; and specialty raw materials and enabling technology solutions in cell and gene therapy, injectable drugs, vaccines, and bio-manufacturing markets. Its Capsules & Health Ingredients segment offers capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical customers. Lonza Group AG was incorporated in 1897 and is headquartered in Basel, Switzerland.